drugset
drugset / Trial / NCT03563950

An Investigational Study to Evaluate the Effect of Rifampin on the Singe Dose of Experimental Medication BMS-986224 in Healthy Participants

NCT03563950 ↗

Phase 1 Completed 42 enrolled Bristol-Myers Squibb
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate if the blood levels of experimental medication BMS-986224 will be changed when given together with Rifampin, an antibiotic that affects specific enzymes involved with the breakdown of BMS-986224.

Timeline

Start
2018-06-01
Primary completion
2018-07-27
Completion
2018-07-27

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-986224 Small molecule — Oral
Subject Rifampicin Small molecule — Oral

Indications

No indication recorded.